Disc Medicine Inc (NAS:IRON)
$ 34.14 -0.52 (-1.5%) Market Cap: 844.00 Mil Enterprise Value: 516.26 Mil PE Ratio: 0 PB Ratio: 2.49 GF Score: 32/100

Disc Medicine Inc KOL Investor Event Transcript

Apr 25, 2023 / 05:00PM GMT
Release Date Price: $30.05 (+0.67%)
John Quisel
Disc Medicine Inc. - CEO

Good afternoon, and thank you for joining us today. My name is John Quisel, and I'm the CEO here at Disc medicine.

Today, we're going to discuss a disorder called Erythropoietic protoporphyria, also referred to as EPP. This is a rare and severe genetic disorder. And our drug development program for the molecule called Bitopertin is now in multiple Phase 2 trials to treat this disorder.

Before I begin, I should note that we may be making forward-looking statements today. Each should be take about context with the language on the slide, as well as in our 10-K and other security filings. We've got an exciting program today. We're delighted to be joined by Professor Bruce Wang from University of California, San Francisco, and also Professor Jean-Charles Deybach, who joins us from Paris University and was the former head of the French Porphyria Centre. And then lastly, we'll have a presentation from Will Savage, the Chief Medical Officer here at Disc Medicine.

First, I'll provide a background about Disc Medicine. We are building what we hope to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot